Gautschi O - Search Results

1

Origin and prognostic value of circulating KRAS mutations in lung cancer patients.

Gautschi O, Huegli B, Ziegler A, Gugger M, Heighway J, Ratschiller D, Mack PC, Gumerlock PH, Kung HJ, Stahel RA, Gandara DR, Betticher DC. Gautschi O, et al. Cancer Lett. 2007 Sep 8;254(2):265-73. doi: 10.1016/j.canlet.2007.03.008. Epub 2007 Apr 20. Cancer Lett. 2007. PMID: 17449174

2

Comment on "Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-call lung cancer patients" (Cancer Letters 2003;193:207-216).

Gautschi O, Ziegler A. Gautschi O, et al. Cancer Lett. 2004 Feb 10;204(1):1. doi: 10.1016/j.canlet.2003.08.026. Cancer Lett. 2004. PMID: 14744528 No abstract available.

3

Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation.

Gautschi O, Ratschiller D, Gugger M, Betticher DC, Heighway J. Gautschi O, et al. Lung Cancer. 2007 Jan;55(1):1-14. doi: 10.1016/j.lungcan.2006.09.024. Epub 2006 Oct 27. Lung Cancer. 2007. PMID: 17070615 Review.

4

Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy.

Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, Chassé E, Ratschiller D, Weder W, Joerger M, Betticher DC, Stahel RA, Ziegler A. Gautschi O, et al. J Clin Oncol. 2004 Oct 15;22(20):4157-64. doi: 10.1200/JCO.2004.11.123. J Clin Oncol. 2004. PMID: 15483026

5

Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients.

Gautschi O, Hugli B, Ziegler A, Bigosch C, Bowers NL, Ratschiller D, Jermann M, Stahel RA, Heighway J, Betticher DC. Gautschi O, et al. Lung Cancer. 2006 Mar;51(3):303-11. doi: 10.1016/j.lungcan.2005.10.025. Epub 2006 Jan 10. Lung Cancer. 2006. PMID: 16406195

6

Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer.

Gautschi O, Tepper CG, Purnell PR, Izumiya Y, Evans CP, Green TP, Desprez PY, Lara PN, Gandara DR, Mack PC, Kung HJ. Gautschi O, et al. Cancer Res. 2008 Apr 1;68(7):2250-8. doi: 10.1158/0008-5472.CAN-07-6403. Cancer Res. 2008. PMID: 18381431

7

The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells.

Purnell PR, Mack PC, Tepper CG, Evans CP, Green TP, Gumerlock PH, Lara PN, Gandara DR, Kung HJ, Gautschi O. Purnell PR, et al. Among authors: gautschi o. J Thorac Oncol. 2009 Apr;4(4):448-54. doi: 10.1097/JTO.0b013e31819c78fb. J Thorac Oncol. 2009. PMID: 19240653 Free PMC article.

8

Aurora kinase inhibitors: a new class of targeted drugs in cancer.

Gautschi O, Mack PC, Davies AM, Lara PN Jr, Gandara DR. Gautschi O, et al. Clin Lung Cancer. 2006 Sep;8(2):93-8. doi: 10.3816/CLC.2006.n.036. Clin Lung Cancer. 2006. PMID: 17026809 Review.

9

[Molecular therapy in lung cancer].

Gautschi O, Betticher DC. Gautschi O, et al. Ther Umsch. 2004 Jun;61(6):365-71. doi: 10.1024/0040-5930.61.6.365. Ther Umsch. 2004. PMID: 15253161 Review. German.

10

Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability.

Smith SL, Bowers NL, Betticher DC, Gautschi O, Ratschiller D, Hoban PR, Booton R, Santibáñez-Koref MF, Heighway J. Smith SL, et al. Among authors: gautschi o. Br J Cancer. 2005 Sep 19;93(6):719-29. doi: 10.1038/sj.bjc.6602779. Br J Cancer. 2005. PMID: 16222316 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

303 results

Search Page

Filters